A61P 37/06
Immunosuppressants
Official title: Immunosuppressants, e.g. drugs for graft rejection
A61P37/06 (Immunosuppressants) appears on 18,476 US grants and 28,869 published applications in this corpus.
Search patents in A61P- Granted patents
- 18,476
- Published applications
- 28,869
- Assignees
- 6,609
- Inventors
- 40,246
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 5 | 0 |
| 1978 | 2 | 0 |
| 1979 | 7 | 0 |
| 1980 | 11 | 0 |
| 1981 | 5 | 0 |
| 1982 | 4 | 0 |
| 1983 | 4 | 0 |
| 1984 | 1 | 0 |
| 1985 | 5 | 0 |
| 1986 | 5 | 0 |
| 1987 | 9 | 0 |
| 1988 | 15 | 0 |
| 1989 | 12 | 0 |
| 1990 | 30 | 0 |
| 1991 | 32 | 0 |
| 1992 | 32 | 0 |
| 1993 | 44 | 0 |
| 1994 | 44 | 0 |
| 1995 | 59 | 0 |
| 1996 | 108 | 0 |
| 1997 | 115 | 0 |
| 1998 | 162 | 0 |
| 1999 | 189 | 0 |
| 2000 | 197 | 0 |
| 2001 | 270 | 60 |
| 2002 | 299 | 481 |
| 2003 | 347 | 827 |
| 2004 | 280 | 1006 |
| 2005 | 307 | 1024 |
| 2006 | 414 | 1116 |
| 2007 | 459 | 1137 |
| 2008 | 502 | 1202 |
| 2009 | 676 | 1549 |
| 2010 | 865 | 1877 |
| 2011 | 976 | 1809 |
| 2012 | 1103 | 1822 |
| 2013 | 1285 | 1392 |
| 2014 | 1246 | 1524 |
| 2015 | 1072 | 1360 |
| 2016 | 994 | 1350 |
| 2017 | 1061 | 1289 |
| 2018 | 904 | 1194 |
| 2019 | 885 | 1247 |
| 2020 | 812 | 984 |
| 2021 | 624 | 935 |
| 2022 | 505 | 874 |
| 2023 | 435 | 783 |
| 2024 | 411 | 829 |
| 2025 | 419 | 693 |
| 2026 | 226 | 505 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cannabidiol nanodrug formulations and methods for use of the same6 Oct 2026US 12,751,959 B2University of Miami
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Composition for preventing or treating inflammatory bowel disease6 Oct 2026US 12,751,979 B2Ajou University Industry-Academic Cooperation Foundation
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Composition for treatment of autoimmune diseases comprising Lactobacillus sakei or extracellular vesicles derived therefrom as active ingredient29 Sep 2026US 12,746,263 B2Liscure Biosciences Co., Ltd.
- Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase8 Oct 2026US 2026/0306487 A1Genentech, Inc.
- Mitochondrial uncouplers for treatment of metabolic diseases and cancer8 Oct 2026US 2026/0306502 A1Mito Biopharma, LLC
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Inhibitor of btk and mutants thereof8 Oct 2026US 2026/0308160 A1
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Drug releasing anastomosis devices and methods for treating anastomotic sites1,779US 7,108,701 B2Ethicon, Inc. · 2006
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001